Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Acorda Therapeutics, Inc. (ACOR : NSDQ)
 
 • Company Description   
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.

Number of Employees: 130

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.68 Daily Weekly Monthly
20 Day Moving Average: 101,604 shares
Shares Outstanding: 13.29 (millions)
Market Capitalization: $9.03 (millions)
Beta: 0.44
52 Week High: $6.36
52 Week Low: $0.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -54.97% -50.66%
12 Week -66.83% -64.01%
Year To Date -71.55% -66.17%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
420 SAW MILL RIVER ROAD
-
ARDSLEY,NY 10502
USA		 ph: 914-347-4300
fax: 914-347-4560		 None http://www.acorda.com
 
 • General Corporate Information   
Officers
Ron Cohen - President; Chief Executive Officer
John P. Kelley - Director and Chair
Michael Gesser - Chief Financial Officer
Peder K. Jensen - Director
Sandra Panem - Director

Peer Information
Acorda Therapeutics, Inc. (CORR.)
Acorda Therapeutics, Inc. (RSPI)
Acorda Therapeutics, Inc. (CGXP)
Acorda Therapeutics, Inc. (BGEN)
Acorda Therapeutics, Inc. (GTBP)
Acorda Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00484M601
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 13.29
Most Recent Split Date: 1.00 (0.17:1)
Beta: 0.44
Market Capitalization: $9.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.07
Price/Cash Flow: -
Price / Sales: 0.07
EPS Growth
vs. Year Ago Period: 45.33%
vs. Previous Quarter: -11.56%
Sales Growth
vs. Year Ago Period: -21.93%
vs. Previous Quarter: -39.04%
ROE
03/31/22 - -60.64
12/31/21 - -58.37
09/30/21 - -0.17
ROA
03/31/22 - -20.91
12/31/21 - -20.82
09/30/21 - -0.06
Current Ratio
03/31/22 - 1.75
12/31/21 - 1.89
09/30/21 - 1.42
Quick Ratio
03/31/22 - 1.39
12/31/21 - 1.55
09/30/21 - 1.12
Operating Margin
03/31/22 - -78.26
12/31/21 - -80.54
09/30/21 - -0.26
Net Margin
03/31/22 - -78.26
12/31/21 - -80.54
09/30/21 - -0.26
Pre-Tax Margin
03/31/22 - -78.81
12/31/21 - -84.51
09/30/21 - -135.37
Book Value
03/31/22 - 9.60
12/31/21 - 13.49
09/30/21 - 14.78
Inventory Turnover
03/31/22 - 1.75
12/31/21 - 1.77
09/30/21 - 1.86
Debt-to-Equity
03/31/22 - 1.43
12/31/21 - 1.18
09/30/21 - 1.07
Debt-to-Capital
03/31/22 - 58.85
12/31/21 - 54.17
09/30/21 - 51.60
 

Powered by Zacks Investment Research ©